Send the following on WhatsApp
Continue to Chathttps://de.marketscreener.com/kurs/aktie/NKGEN-BIOTECH-INC-159962988/news/NKGen-Biotech-Inc-gibt-die-Verabreichung-des-ersten-Patienten-in-seiner-Phase-1-2a-Studie-mit-dem-45647710/?utm_source=whatsapp&utm_medium=social&utm_campaign=share